Valuation: BioNTech SE

Market Cap 20.2B 23.4B 18.95B 17.26B 32.45B 2,237B 32.9B 222B 87.04B 1,121B 87.84B 85.93B 3,728B P/E 2026 *
-14.6x
P/E 2027 * -15.2x
Enterprise Value 9.42B 10.91B 8.84B 8.05B 15.13B 1,043B 15.34B 104B 40.59B 523B 40.96B 40.07B 1,738B EV / Sales 2026 *
5.15x
EV / Sales 2027 * 5.77x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-21.51%+2.41% - - 23.38B
+4.80%+7.80%+70.64%+114.21% 70.07B
+17.12%+11.50%+49.15%+87.30% 52.87B
+3.20%-5.35%+0.21%+480.52% 27.02B
+2.26%+0.65%+49.19%+10.30% 23.61B
-1.32%-1.05%-18.41%-18.89% 23.38B
-6.00%+13.71%+244.39%+443.26% 19.43B
+3.80%+5.62%+39.57%-15.26% 18.75B
+0.38%-3.15%+20.39%+589.77% 15.85B
+2.62%-0.76%+39.18%+150.26% 12.7B
Average +2.92%-2.08%+54.92%+204.61% 29.3B
Weighted average by Cap. +4.87%-1.14%+55.35%+170.62%

Financials

2026 *2027 *
Net sales 1.83B 2.12B 1.72B 1.56B 2.94B 203B 2.98B 20.13B 7.89B 102B 7.96B 7.79B 338B 1.86B 2.16B 1.75B 1.59B 3B 206B 3.04B 20.5B 8.03B 103B 8.11B 7.93B 344B
Net income -1.34B -1.55B -1.26B -1.15B -2.15B -148B -2.18B -14.74B -5.78B -74.39B -5.83B -5.7B -247B -1.34B -1.55B -1.26B -1.14B -2.15B -148B -2.18B -14.73B -5.77B -74.31B -5.82B -5.7B -247B
Net Debt -10.78B -12.49B -10.11B -9.21B -17.32B -1,194B -17.56B -119B -46.45B -598B -46.88B -45.86B -1,990B -9.44B -10.94B -8.86B -8.07B -15.17B -1,046B -15.38B -104B -40.69B -524B -41.06B -40.17B -1,743B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
-